A daily pill used alongside chemotherapy has halted the growth of pancreatic tumours in the vast majority of patients in a new clinical trial, in what experts are calling the most significant advance in pancreatic cancer treatment in decades. The drug, daraxonrasib, has shown the potential to shrink or even eliminate tumours in some cases, offering fresh hope against one of the most lethal forms of cancer.
According to trial results presented by Dr. Wungki Park of Memorial Sloan Kettering Cancer Center, tumours stopped growing in 90% of the 61 participants with advanced pancreatic cancer who received daraxonrasib in combination with standard chemotherapy. More than 60% of patients saw their tumours shrink or disappear, and in one in 12 patients, no cancer was detectable on CT scans following treatment.
Dr. Park described the findings as unprecedented, stating, “This is the closest to cure,” after observing tumours vanish in patients whose cancer had already spread to other organs. Cancer Research UK echoed this sentiment, calling the results “the biggest leap forward we’ve seen in decades for pancreatic cancer patients.”
The trial focused on patients recently diagnosed with advanced pancreatic cancer, a disease often referred to as a “silent killer” due to its subtle symptoms and rapid progression. Pancreatic cancer has the lowest survival rate among common cancers in the UK, with half of all patients dying within three months of diagnosis and only about 3% surviving for five years if the cancer has metastasized.
Daraxonrasib, also known as Rasonque, is a pan-RAS inhibitor designed to target a key driver of tumour growth. The drug’s objective response rate in the trial reached nearly 61%, including 8% of patients achieving a complete response, meaning their tumours were no longer detectable. The disease control rate—patients whose cancer stopped growing or shrank—exceeded 90%, according to updated data presented at the EORTC-NCI-AACR Symposium in Barcelona.
Experts not involved in the study, such as Professor Shivan Sivakumar of the University of Birmingham, highlighted the potential of daraxonrasib to move pancreatic cancer treatment beyond chemotherapy, which has long been the mainstay despite limited effectiveness. “What is particularly exciting is the potential to move beyond chemotherapy as the mainstay of treatment for pancreatic cancer,” Sivakumar said.
Michelle Mitchell, chief executive of Cancer Research UK, said the pill represents a “massive hope” for patients facing a disease with few effective options. The charity emphasised the urgent need for new treatments, given the poor prognosis and late detection associated with pancreatic cancer.
Despite the encouraging results, researchers caution that the findings are still early and based on a relatively small group of patients. Further studies are needed to confirm the long-term benefits and to determine whether these outcomes can be replicated in larger, more diverse populations. The availability of the pill for wider use will depend on the results of ongoing and future clinical trials.
Why it matters
The emergence of daraxonrasib as a potential new standard in pancreatic cancer treatment marks a significant shift for patients and clinicians. Pancreatic cancer has long been one of the deadliest cancers, with survival rates lagging far behind those for other common cancers. According to Cancer Research UK, the disease has seen little progress in outcomes for decades, making these new results particularly significant.
For patients, the prospect of a daily pill that can stop tumour growth and, in some cases, make cancer undetectable, offers hope where few options previously existed. Dr. Wungki Park’s statement that this is “the closest to cure” underscores the scale of the advance, especially for those with advanced or metastatic disease who typically face a grim prognosis.
The trial’s success also signals potential changes for future research and treatment approaches. As Professor Sivakumar highlighted, the ability to move beyond chemotherapy could pave the way for combination therapies and more targeted interventions. With further trials planned and ongoing, the oncology community will be watching closely to see if daraxonrasib can deliver lasting improvements in survival and quality of life for pancreatic cancer patients worldwide.
The image accompanying this article is an AI-generated illustrative depiction inspired by the actual scene of the event.































